Resarch of the effect of antiviral drugs on the suppression of COVID-19 persistent symptoms
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000048380
- Lead Sponsor
- agasaki University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 382
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients diagnosed with moderate or severe COVID-19 at the time of first visit (2) Patients diagnosed with COVID-19 during hospitalization (3) Patients with COVID-19 who were started on antiviral drugs during hospitalization (4) Other patients deemed inappropriate as research subjects by the investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of COVID-19 persistent symptoms at 12 weeks after first visit
- Secondary Outcome Measures
Name Time Method Development of COVID-19 persistent symptoms at 28 days, 24 weeks, 36 weeks, and 48 weeks after first visit Comparison of patient background (age, days of disease onset, number of SARS-Cov-2 vaccinations, risk of COVID-19 severity) in each group Search for predictive factors for the development of COVID-19 persistent symptoms using blood samples Hospitalization rate within 28 days of first visit